Add like
Add dislike
Add to saved papers

The influence on pregnancy of anti-SSA/Ro antibodies in systemic lupus erythematosus.

Excessive fetal morbidity and mortality have been noted in patients with systemic lupus erythematosus (SLE). The influence of anti-SSA/Ro antibodies on fetal outcome in SLE patients has rarely been reported, but its high association with congenital heart block or neonatal lupus syndrome is well known. In 430 pregnancies of the 154 SLE patients studied, there was an increased frequency of adverse fetal outcome compared with controls. There was no significant difference in the rates of adverse fetal outcome between anti-SSA/Ro positive and negative SLE patients, except that the incidence of intrauterine growth retardation increased in the positive patients. However, pregnant SLE patients with high titer of anti-SSA/Ro antibodies had more adverse fetal outcomes. All three infants who suffered congenital heart block/neonatal lupus syndrome were associated with maternal anti-SSA/Ro antibodies. The frequency of congenital heart block/neonatal lupus syndrome was 0.79% (3/379) in livebirths of all SLE patients and 1.17% (3/257) in live-births by anti-SSA/Ro positive SLE mothers.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app